Changzhou Qianhong Biopharma Co Ltd Asset Resilience Ratio
Changzhou Qianhong Biopharma Co Ltd asset resilience ratio. Changzhou Qianhong Biopharma Co Ltd (002550) has an Asset Resilience Ratio of 18.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002550 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Changzhou Qianhong Biopharma Co Ltd (2007–2025)
Asset resilience ratio of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025. This chart shows how Changzhou Qianhong Biopharma Co Ltd's Asset Resilience Ratio has changed over time. Read debt load of Changzhou Qianhong Biopharma Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Changzhou Qianhong Biopharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002550 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥604.36 Million | 18.7% |
| Total Liquid Assets | CN¥604.36 Million | 18.70% |
Asset Resilience Insights
- Good Liquidity Position: Changzhou Qianhong Biopharma Co Ltd maintains a healthy 18.70% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Changzhou Qianhong Biopharma Co Ltd Industry Peers by Asset Resilience Ratio
Compare Changzhou Qianhong Biopharma Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Changzhou Qianhong Biopharma Co Ltd Asset Resilience Ratio by Year (2007–2025)
Changzhou Qianhong Biopharma Co Ltd asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Changzhou Qianhong Biopharma Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.24% | CN¥594.02 Million ≈ $86.92 Million |
CN¥3.09 Billion ≈ $451.70 Million |
+9.57pp |
| 2024-12-31 | 9.67% | CN¥273.83 Million ≈ $40.07 Million |
CN¥2.83 Billion ≈ $414.18 Million |
+4.72pp |
| 2023-12-31 | 4.95% | CN¥136.93 Million ≈ $20.04 Million |
CN¥2.77 Billion ≈ $404.76 Million |
+2.55pp |
| 2022-12-31 | 2.40% | CN¥67.48 Million ≈ $9.87 Million |
CN¥2.81 Billion ≈ $410.60 Million |
-0.32pp |
| 2021-12-31 | 2.72% | CN¥68.23 Million ≈ $9.98 Million |
CN¥2.51 Billion ≈ $367.06 Million |
-6.84pp |
| 2020-12-31 | 9.56% | CN¥234.28 Million ≈ $34.28 Million |
CN¥2.45 Billion ≈ $358.77 Million |
-13.04pp |
| 2019-12-31 | 22.59% | CN¥662.98 Million ≈ $97.01 Million |
CN¥2.93 Billion ≈ $429.38 Million |
-19.09pp |
| 2018-12-31 | 41.69% | CN¥1.32 Billion ≈ $193.89 Million |
CN¥3.18 Billion ≈ $465.09 Million |
-10.30pp |
| 2017-12-31 | 51.99% | CN¥1.58 Billion ≈ $231.61 Million |
CN¥3.04 Billion ≈ $445.48 Million |
-- |
| 2016-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥3.03 Billion ≈ $443.95 Million |
-- |
| 2015-12-31 | 0.36% | CN¥10.25 Million ≈ $1.50 Million |
CN¥2.83 Billion ≈ $414.58 Million |
-0.08pp |
| 2014-12-31 | 0.44% | CN¥10.23 Million ≈ $1.50 Million |
CN¥2.31 Billion ≈ $338.13 Million |
+0.43pp |
| 2013-12-31 | 0.02% | CN¥362.70K ≈ $53.07K |
CN¥2.07 Billion ≈ $302.36 Million |
0.00pp |
| 2012-12-31 | 0.02% | CN¥338.65K ≈ $49.56K |
CN¥1.93 Billion ≈ $282.04 Million |
0.00pp |
| 2011-12-31 | 0.02% | CN¥369.85K ≈ $54.12K |
CN¥1.85 Billion ≈ $271.18 Million |
-0.06pp |
| 2010-12-31 | 0.08% | CN¥431.60K ≈ $63.16K |
CN¥548.53 Million ≈ $80.27 Million |
-0.01pp |
| 2009-12-31 | 0.09% | CN¥464.10K ≈ $67.91K |
CN¥533.87 Million ≈ $78.12 Million |
0.00pp |
| 2008-12-31 | 0.09% | CN¥353.60K ≈ $51.74K |
CN¥391.74 Million ≈ $57.32 Million |
-0.15pp |
| 2007-12-31 | 0.24% | CN¥683.80K ≈ $100.06K |
CN¥288.56 Million ≈ $42.23 Million |
-- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more